Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.
Meinolf
M
Suttorp
Christian
C
Thiede
Josephine T
JT
Tauer
Ursula
U
Range
Brigitte
B
Schlegelberger
Nils
N
von Neuhoff
D000293:Adolescent; D001549:Benzamides; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D007223:Infant; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D014158:Transcription, Genetic / Q000235:genetics; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl